IDYA 8-K
IDEAYA Biosciences, Inc. (IDYA)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|||
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 4, 2025, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
IDEAYA BIOSCIENCES, INC. |
|
|
|
Date: November 4, 2025 |
By: |
/s/ Yujiro Hata |
|
|
Yujiro Hata |
|
|
President and Chief Executive Officer |
Exhibit 99.1
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results for the third quarter ended September 30, 2025.
"This quarter we continued to make significant progress across the pipeline and broader business, including the partnership with Servier that extends our runway into 2030 and enables potential commercialization of darovasertib outside of the United States. We have also provided multiple major medical conference clinical data updates at WCLC, ESMO and SMR, and completed our third IND filing in 2025 to further extend our industry leadership in precision medicine oncology," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.
Selected Pipeline Developments and Upcoming Milestones
Exhibit 99.1
Darovasertib
Exhibit 99.1
IDE397 (MAT2A)
IDE849 (DLL3 TOP1i ADC)
Exhibit 99.1
Other programs
Exhibit 99.1
License agreement with Servier
Financial Results for the Quarter Ended September 30, 2025
As of September 30, 2025, IDEAYA had cash, cash equivalents and marketable securities of approximately $1.14 billion, compared to $991.9 million as of June 30, 2025. The increase was primarily driven by the $210.0 million upfront payment received from Servier related to the exclusive license agreement for darovasertib, offset by the net cash used in operations.
Collaboration revenue for the three months ended September 30, 2025, totaled $207.8 million compared to zero for the three months ended June 30, 2025. Collaboration revenue was recognized for the performance obligations satisfied through September 30, 2025 related to the development and commercialization license recognized upon execution and the research and development services that will be recognized over time under the Servier exclusive license agreement for darovasertib. As of September 30, 2025, the remaining balance for the research and development services performance obligations is $143.1 million related to the clinical development cost reimbursements anticipated under the license agreement that will be recognized as IDEAYA collaboration revenue over time as the research and development services are completed.
Research and development (R&D) expenses for the three months ended September 30, 2025 totaled $83.0 million compared to $74.2 million for the three months ended June 30, 2025. The increase was primarily driven by higher clinical trial and CMC manufacturing expenses to support our programs.
General and administrative (G&A) expenses for the three months ended September 30, 2025 totaled $16.4 million compared to $14.6 million for the three months ended June 30, 2025. The increase was primarily due to higher legal expenses to support company growth and commercial expenses to support the darovasertib commercial preparation activities.
Exhibit 99.1
The net income for the three months ended September 30, 2025, was $119.2 million compared to the net loss of $77.5 million for the three months ended June 30, 2025. Total stock compensation expense for the three months ended September 30, 2025, was $12.2 million compared to $11.9 million for the three months ended June 30, 2025.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. IDEAYA's corporate presentation is available on its website: https://ir.ideayabio.com/.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the timing and content of clinical trial programs and updates, including enrollment achievements, regulatory updates, clinical trial data readouts, including those at medical conferences; (ii) the potential for an accelerated approval filing for darovasertib; (iii) the potential therapeutic benefits of IDEAYA therapeutics; (iv) the translation of preliminary clinical trial results into future clinical trial results and/or regulatory approval; (v) timing of development and regulatory milestones; (vi) the timing of new IND application filings; (vii) the potential for milestone payments, royalties and clinical development cost sharing under the Servier License Agreement; and (viii) the extent to which IDEAYA's existing cash, cash equivalents, and marketable securities will fund its planned operations. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing and commercializing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA
Exhibit 99.1
undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
[email protected]
Exhibit 99.1
IDEAYA Biosciences, Inc.
Condensed Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share amounts)
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
September 30, 2025 |
|
|
June 30, 2025 |
|
|
September 30, 2025 |
|
|
September 30, 2024 |
|
||||
|
|
(Unaudited) |
|
|
(Unaudited) |
|
||||||||||
Collaboration revenue |
|
$ |
207,834 |
|
|
$ |
— |
|
|
$ |
207,834 |
|
|
$ |
— |
|
Total revenue |
|
|
207,834 |
|
|
|
— |
|
|
|
207,834 |
|
|
|
— |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
82,993 |
|
|
$ |
74,226 |
|
|
$ |
228,105 |
|
|
$ |
154,490 |
|
General and administrative |
|
|
16,389 |
|
|
|
14,580 |
|
|
|
44,472 |
|
|
|
28,347 |
|
Total operating expenses |
|
|
99,382 |
|
|
|
88,806 |
|
|
|
272,577 |
|
|
|
182,837 |
|
Income (loss) from operations |
|
|
108,452 |
|
|
|
(88,806 |
) |
|
|
(64,743 |
) |
|
|
(182,837 |
) |
Interest income and other income, net |
|
|
10,792 |
|
|
|
11,315 |
|
|
|
34,318 |
|
|
|
38,672 |
|
Net income (loss) |
|
|
119,244 |
|
|
|
(77,491 |
) |
|
|
(30,425 |
) |
|
|
(144,165 |
) |
Unrealized gains on marketable securities |
|
|
531 |
|
|
|
(64 |
) |
|
|
1,240 |
|
|
|
3,274 |
|
Comprehensive income (loss) |
|
$ |
119,775 |
|
|
$ |
(77,555 |
) |
|
$ |
(29,185 |
) |
|
$ |
(140,891 |
) |
Net income (loss) per share |
|
$ |
1.35 |
|
|
$ |
(0.88 |
) |
|
$ |
(0.34 |
) |
|
$ |
(1.81 |
) |
Weighted-average number of shares |
|
|
88,526,781 |
|
|
|
88,472,197 |
|
|
|
88,452,395 |
|
|
|
79,776,728 |
|
Net income (loss) per share |
|
$ |
1.33 |
|
|
$ |
(0.88 |
) |
|
$ |
(0.34 |
) |
|
$ |
(1.81 |
) |
Weighted-average number of shares |
|
|
89,690,878 |
|
|
|
88,472,197 |
|
|
|
88,452,395 |
|
|
|
79,776,728 |
|
Exhibit 99.1
IDEAYA Biosciences, Inc.
Condensed Balance Sheet Data
(in thousands)
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2025 |
|
|
2024 |
|
||
|
|
(Unaudited) |
|
|||||
Cash and cash equivalents and short-term and long-term marketable securities |
|
$ |
1,136,854 |
|
|
$ |
1,082,151 |
|
Total assets |
|
|
1,185,136 |
|
|
|
1,124,091 |
|
Total liabilities |
|
|
93,102 |
|
|
|
64,944 |
|
Total liabilities and stockholders' equity |
|
$ |
1,185,136 |
|
|
$ |
1,124,091 |
|